Marine Compounds and Cancer 2020
The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the las...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2021 |
| Language: | English |
| Physical Description: | 1 electronic resource (480 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 12789nam-a2204429z--4500 | ||
|---|---|---|---|
| 001 | 993545616304498 | ||
| 005 | 20231214133147.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202201s2021 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000042485 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/76418 | ||
| 035 | |a (EXLCZ)995400000000042485 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Honecker, Friedemann |4 edt | |
| 245 | 1 | 0 | |a Marine Compounds and Cancer 2020 |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (480 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a apoptosis | ||
| 653 | |a fucoidan | ||
| 653 | |a hepatocellular carcinoma | ||
| 653 | |a reactive oxygen species | ||
| 653 | |a 3-alkylpyridinium polymers | ||
| 653 | |a nicotine | ||
| 653 | |a nicotinic acetylcholine receptor | ||
| 653 | |a non-small cell lung carcinoma | ||
| 653 | |a melanoma | ||
| 653 | |a sinulariolide | ||
| 653 | |a proteomic | ||
| 653 | |a mitochondria | ||
| 653 | |a caspase cascade | ||
| 653 | |a marine fungus | ||
| 653 | |a sediment | ||
| 653 | |a anthranilic acid | ||
| 653 | |a Penicillium paneum | ||
| 653 | |a cytotoxicity | ||
| 653 | |a dibromotyrosine | ||
| 653 | |a mitochondrial dysfunction | ||
| 653 | |a oxidative stress | ||
| 653 | |a topoisomerase | ||
| 653 | |a epigonal organ | ||
| 653 | |a bonnethead shark | ||
| 653 | |a Jurkat | ||
| 653 | |a tumor cell line | ||
| 653 | |a hippuristanol | ||
| 653 | |a PEL | ||
| 653 | |a AP-1 | ||
| 653 | |a STAT3 | ||
| 653 | |a Akt | ||
| 653 | |a colorectal cancer | ||
| 653 | |a marine mollusc | ||
| 653 | |a brominated indoles | ||
| 653 | |a shrimp | ||
| 653 | |a chemoprevention | ||
| 653 | |a fatty acids | ||
| 653 | |a carotenoids | ||
| 653 | |a cancer | ||
| 653 | |a nanoparticle | ||
| 653 | |a osteosarcoma | ||
| 653 | |a lung metastasis | ||
| 653 | |a elisidepsin | ||
| 653 | |a lipid rafts | ||
| 653 | |a hydroxylated lipids | ||
| 653 | |a fatty acid 2-hydroxylase | ||
| 653 | |a cooperative binding | ||
| 653 | |a membrane permeabilization | ||
| 653 | |a marine organisms | ||
| 653 | |a polysaccharides | ||
| 653 | |a anticancer | ||
| 653 | |a anticarcinogenic | ||
| 653 | |a mechanisms of action | ||
| 653 | |a fumigaclavine C | ||
| 653 | |a anti-proliferation | ||
| 653 | |a mitochondrial pathway | ||
| 653 | |a anti-cancer | ||
| 653 | |a anti-proliferative | ||
| 653 | |a carotenoid | ||
| 653 | |a cell cycle arrest | ||
| 653 | |a fucoxanthin | ||
| 653 | |a azoxymethane | ||
| 653 | |a bioactive natural product | ||
| 653 | |a isatin | ||
| 653 | |a in vivo model | ||
| 653 | |a Marthasterias glacialis L. | ||
| 653 | |a palmitic acid | ||
| 653 | |a ER-stress | ||
| 653 | |a CHOP | ||
| 653 | |a Antibody Drug Conjugates (ADCs) | ||
| 653 | |a marine antitumor agents | ||
| 653 | |a clinical trials | ||
| 653 | |a approved antitumor agents | ||
| 653 | |a AD0157 | ||
| 653 | |a angiogenesis | ||
| 653 | |a marine drug | ||
| 653 | |a pyrrolidinedione | ||
| 653 | |a secondary metabolites | ||
| 653 | |a cancer preventive | ||
| 653 | |a chemopreventive | ||
| 653 | |a trabectedin | ||
| 653 | |a plitidepsin | ||
| 653 | |a tumor-associated macrophages | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a preclinical | ||
| 653 | |a anticancer immunity | ||
| 653 | |a antiangiogenesis | ||
| 653 | |a fascaplysin | ||
| 653 | |a cyclin-dependent kinase | ||
| 653 | |a small cell lung cancer | ||
| 653 | |a camptothecin | ||
| 653 | |a poly(ADP-ribose)-polymerase inhibitor | ||
| 653 | |a breast cancer | ||
| 653 | |a seaweed | ||
| 653 | |a therapeutic compounds | ||
| 653 | |a autophagy | ||
| 653 | |a marine drugs | ||
| 653 | |a autophagy inhibitors | ||
| 653 | |a autophagy inducers | ||
| 653 | |a macrolide | ||
| 653 | |a programmed cell death | ||
| 653 | |a energy stress | ||
| 653 | |a araguspongine C | ||
| 653 | |a c-Met | ||
| 653 | |a HER2 | ||
| 653 | |a gemcitabine | ||
| 653 | |a pazopanib | ||
| 653 | |a phase I | ||
| 653 | |a safety | ||
| 653 | |a soft tissue sarcoma | ||
| 653 | |a pachastrissamine | ||
| 653 | |a jaspine B | ||
| 653 | |a carbocyclic analogue | ||
| 653 | |a sphingosine kinase inhibitor | ||
| 653 | |a molecular modeling | ||
| 653 | |a ET-743 | ||
| 653 | |a DNA minor groove binder | ||
| 653 | |a soft tissue sarcoma | ||
| 653 | |a chemotherapy | ||
| 653 | |a bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane (BDDPM) | ||
| 653 | |a anti-metastatic activity | ||
| 653 | |a cell adhesion | ||
| 653 | |a β1-integrin | ||
| 653 | |a FAK | ||
| 653 | |a BEL-7402 cell | ||
| 653 | |a triterpene glycosides | ||
| 653 | |a sea cucumbers | ||
| 653 | |a antitumor activities | ||
| 653 | |a arrest of cell cycle | ||
| 653 | |a antibacterial | ||
| 653 | |a marangucyclines | ||
| 653 | |a deep-sea | ||
| 653 | |a Streptomyces sp. SCSIO 11594 | ||
| 653 | |a LS-1 | ||
| 653 | |a SNU-C5/5-FU | ||
| 653 | |a TGF-β signaling | ||
| 653 | |a carcinoembryonic antigen | ||
| 653 | |a kalkitoxin | ||
| 653 | |a Moorea producens | ||
| 653 | |a mitochondria toxin | ||
| 653 | |a VEGF | ||
| 653 | |a angiogenesis inhibitor | ||
| 653 | |a hypoxia-inducible factor-1 | ||
| 653 | |a HIF-1 | ||
| 653 | |a Lyngbya majuscula | ||
| 653 | |a marine metabolites | ||
| 653 | |a SZ-685C | ||
| 653 | |a nonfunctioning pituitary adenomas | ||
| 653 | |a Ecklonia cava | ||
| 653 | |a phlorotannins | ||
| 653 | |a dieckol | ||
| 653 | |a migration | ||
| 653 | |a sipholenol A | ||
| 653 | |a ABC transporter | ||
| 653 | |a multidrug resistance | ||
| 653 | |a P-gp/ABCB1 | ||
| 653 | |a BCRP/ABCG2 | ||
| 653 | |a MRP1/ABCC1 | ||
| 653 | |a marine natural products | ||
| 653 | |a glioblastoma | ||
| 653 | |a xyloketal B | ||
| 653 | |a proliferation | ||
| 653 | |a TRPM7 | ||
| 653 | |a marine compound | ||
| 653 | |a ribosomal protein genes | ||
| 653 | |a snoRNA | ||
| 653 | |a FAU | ||
| 653 | |a RPS30 | ||
| 653 | |a SNORA62 | ||
| 653 | |a evolution | ||
| 653 | |a Porifera | ||
| 653 | |a Penicillium brevicompactum | ||
| 653 | |a Brevianamide | ||
| 653 | |a Mycochromenic acid derivative | ||
| 653 | |a antifouling | ||
| 653 | |a Caribbean sponge | ||
| 653 | |a plakortide | ||
| 653 | |a endoperoxide | ||
| 653 | |a leukemia | ||
| 653 | |a multi-drug resistant leukemia | ||
| 653 | |a Sarcophyton ehrenbergi | ||
| 653 | |a soft coral | ||
| 653 | |a terpenes | ||
| 653 | |a cembranoids | ||
| 653 | |a cytotoxic activity | ||
| 653 | |a molecular docking | ||
| 653 | |a uveal melanoma | ||
| 653 | |a oxidative stress | ||
| 653 | |a virtual screening | ||
| 653 | |a Topo I inhibitor | ||
| 653 | |a low toxic | ||
| 653 | |a natural product | ||
| 653 | |a Ulva fasciata | ||
| 653 | |a selenium-containing polysaccharide-protein complex | ||
| 653 | |a pseudopterosin | ||
| 653 | |a NF-κB | ||
| 653 | |a p65 | ||
| 653 | |a inflammation | ||
| 653 | |a cytokine release | ||
| 653 | |a IL-6 | ||
| 653 | |a TNFα | ||
| 653 | |a MCP-1 | ||
| 653 | |a glucocorticoid receptor | ||
| 653 | |a paulomycins | ||
| 653 | |a Micromonospora | ||
| 653 | |a antitumor | ||
| 653 | |a Cantabrian Sea-derived actinobacteria | ||
| 653 | |a puupehenones | ||
| 653 | |a sponges | ||
| 653 | |a antiangiogenic | ||
| 653 | |a antitumoral | ||
| 653 | |a porifera/sponge | ||
| 653 | |a cancer genes | ||
| 653 | |a molecular oncology | ||
| 653 | |a bromophenol | ||
| 653 | |a molecular mechanisms | ||
| 653 | |a cell cycle | ||
| 653 | |a PI3K/Akt | ||
| 653 | |a p38/ERK | ||
| 653 | |a ROS | ||
| 653 | |a human lung cancer | ||
| 653 | |a glycosaminoglycans | ||
| 653 | |a antiproliferative | ||
| 653 | |a heparan sulphate | ||
| 653 | |a gliotoxin | ||
| 653 | |a NSCLC | ||
| 653 | |a adriamycin resistance | ||
| 653 | |a Sepia ink polysaccharides | ||
| 653 | |a antitumour | ||
| 653 | |a chemosensitization | ||
| 653 | |a anticoagulation | ||
| 653 | |a sea anemone | ||
| 653 | |a drug discovery | ||
| 653 | |a endothelial cells | ||
| 653 | |a RGD motif | ||
| 653 | |a kunitz type inhibitor | ||
| 653 | |a prostate cancer | ||
| 653 | |a antioxidant | ||
| 653 | |a natural marine compounds | ||
| 653 | |a marine biotechnology | ||
| 653 | |a microalgae | ||
| 653 | |a marine sponges | ||
| 653 | |a Aeroplysinin | ||
| 653 | |a Isofistularin | ||
| 653 | |a pheochromocytoma and paraganglioma | ||
| 653 | |a metastasis | ||
| 653 | |a cancer progression | ||
| 653 | |a cell adhesion molecules | ||
| 653 | |a integrin β1 | ||
| 653 | |a hypoxia | ||
| 653 | |a phycocyanin | ||
| 653 | |a non-small cell lung cancer | ||
| 653 | |a NF-κB signaling | ||
| 653 | |a marine-derived drugs | ||
| 653 | |a bioanalysis | ||
| 653 | |a chromatography | ||
| 653 | |a manzamine A | ||
| 653 | |a epithelial-mesenchymal transition | ||
| 653 | |a lung cancer | ||
| 653 | |a circulating tumor cells | ||
| 653 | |a signal transduction | ||
| 653 | |a cisplatin | ||
| 653 | |a Lampetra morii | ||
| 653 | |a buccal gland | ||
| 653 | |a cystatin F | ||
| 653 | |a anti-angiogenesis | ||
| 653 | |a cystatin superfamily | ||
| 653 | |a Antimicrobial peptide (AMP) | ||
| 653 | |a Tilapia piscidin 4 (TP4) | ||
| 653 | |a non-small cell lung cancer (NSCLC) | ||
| 653 | |a itampolin A | ||
| 653 | |a FBDD | ||
| 653 | |a p38α | ||
| 653 | |a novel inhibitor | ||
| 653 | |a tetracenomycin X | ||
| 653 | |a cyclin D1 | ||
| 653 | |a proteasomal degradation | ||
| 653 | |a p38 | ||
| 653 | |a c-JUN | ||
| 653 | |a λ-carrageenan | ||
| 653 | |a heparanase | ||
| 653 | |a anticoagulant | ||
| 653 | |a depolymerisation | ||
| 653 | |a cell migration | ||
| 653 | |a Aspergillus | ||
| 653 | |a naphthopyrones | ||
| 653 | |a endophytic fungus | ||
| 653 | |a Leathesia nana | ||
| 653 | |a mangrove-derived actinomycete | ||
| 653 | |a ansamycins | ||
| 653 | |a divergolides | ||
| 653 | |a apoptosis-inducing activity | ||
| 653 | |a actinomycin | ||
| 653 | |a EMT | ||
| 653 | |a invasion | ||
| 653 | |a low molecular weight fucoidan extract | ||
| 653 | |a N-Ras | ||
| 653 | |a neuroblastoma-rat sarcoma | ||
| 653 | |a Cancer | ||
| 653 | |a programmed cell death-ligand 1 | ||
| 653 | |a programmed cell death-ligand 2 | ||
| 653 | |a human sarcoma cell line (HT1080 cells) | ||
| 653 | |a human normal diploid fibroblast (TIG-1 cells) | ||
| 653 | |a chimera | ||
| 653 | |a chemical conjugation | ||
| 653 | |a anticancer agent | ||
| 653 | |a hybridization | ||
| 653 | |a α9-nicotinic acetylcholine receptors (nAChRs) | ||
| 653 | |a breast cancer cells | ||
| 653 | |a αO-conotoxin GeXIVA | ||
| 653 | |a targeted therapy | ||
| 653 | |a gorgonian | ||
| 653 | |a Leptogorgia | ||
| 653 | |a humulane sesquiterpenoids | ||
| 653 | |a anticancer activity | ||
| 653 | |a 12-deacetyl-12-epi-scalaradial | ||
| 653 | |a HeLa cells | ||
| 653 | |a Nur77 | ||
| 653 | |a MAPK/ERK pathway | ||
| 653 | |a Mycalin A | ||
| 653 | |a C15 acetogenins | ||
| 653 | |a synthetic analogues | ||
| 653 | |a antiproliferative activity | ||
| 653 | |a A375 and HeLa cell lines | ||
| 653 | |a polyoxygenated steroids | ||
| 653 | |a sponge | ||
| 653 | |a Haliclona gracilis | ||
| 653 | |a Thalassia testudinum | ||
| 653 | |a thalassiolin B | ||
| 653 | |a polyphenols | ||
| 653 | |a CYP1A1 | ||
| 653 | |a benzo[a]pyrene | ||
| 653 | |a JNK1/2 | ||
| 653 | |a natural products | ||
| 653 | |a synergism | ||
| 653 | |a A549 cells | ||
| 653 | |a cytoskeleton | ||
| 653 | |a P2X7 receptor | ||
| 653 | |a pollution | ||
| 653 | |a anti-angiogenic | ||
| 653 | |a gene expression | ||
| 653 | |a HSP90 | ||
| 653 | |a inhibitor | ||
| 776 | |z 3-0365-0630-6 | ||
| 776 | |z 3-0365-0631-4 | ||
| 700 | 1 | |a Dyshlovoy, Sergey A. |4 edt | |
| 700 | 1 | |a Honecker, Friedemann |4 oth | |
| 700 | 1 | |a Dyshlovoy, Sergey A. |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:44:47 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337997490004498&Force_direct=true |Z 5337997490004498 |b Available |8 5337997490004498 | ||